Efthymios Ziogos

Lipoprotein(a) concentrations in acute myocardial infarction patients are not indicative of levels at six month follow-up

Efthymios Ziogos, Michael Vavuranakis, Tarek Harb et al. · European Heart Journal Open · 2023 · 37 citations · Full text

Medicine, Cardiology, Internal Medicine +17

The Trajectory of Lipoprotein(a) During the Peri- and Early Postinfarction Period and the Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition

Michael Vavuranakis, Steven R. Jones, Efthymios Ziogos et al. · The American Journal of Cardiology · 2022 · 36 citations

Life Sciences, Biochemistry, Cardiology +13

Intra-individual variability in lipoprotein(a): the value of a repeat measure for reclassifying individuals at intermediate risk

Tarek Harb, Efthymios Ziogos, Roger S. Blumenthal et al. · European Heart Journal Open · 2024 · 31 citations · Full text

Public Health, Biostatistics, Clinical Epidemiology +16

Platelet activation and endothelial dysfunction biomarkers in acute coronary syndrome: the impact of PCSK9 inhibition

Efthymios Ziogos, Stephen P. Chelko, Tarek Harb et al. · European Heart Journal - Cardiovascular Pharmacotherapy · 2023 · 30 citations · Full text

Medicine, Cardiology, Pharmacology +17

Rapid Improvement of Coronary Endothelial Function With PCSK9 Inhibition in People With HIV Is Associated With Reduced Lipoprotein (a) and Not LDL-cholesterol

Tarek Harb, Efthymios Ziogos, Michael Schär et al. · Circulation Cardiovascular Imaging · 2023 · 11 citations · Full text

Medicine, Cardiology, Pharmacotherapy +17